1

Title: Evaluation of Different Types of Face Masks to Limit the Spread of SARS-CoV-2 – A

Modeling Study

Authors: Brian M. Gurbaxani, PhD*; Andrew N. Hill, PhD*; Prabasaj Paul, PhD; Pragati V.

Prasad, MPH; Rachel B. Slayton, PhD.

*These authors contributed equally to this work

Affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Article Summary Line: Adapting a published SARS-CoV-2 transmission model together with

updated, laboratory-derived source control and wearer protection efficacy estimates for a variety

of face coverings as well as N95 respirators, we demonstrate that community masking as

currently practiced has likely reduced cases and deaths and that this benefit can be increased with

wider adoption of better performing masks.

Running Title: Evaluation of Face Masks to Limit SARS-CoV-2

Keywords: 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; coronavirus;

mathematical modeling; severe acute respiratory syndrome coronavirus 2; face masks.

All text: Times New Roman 12-pt. font; double-spaced and left aligned (left-justified).

Manuscript Number:

Abstract – WC 149 (Limit is 150!):

We updated a published mathematical model of SARS-CoV-2 transmission with laboratory-derived source and wearer protection efficacy estimates for a variety of face masks to estimate their impact on COVID-19 incidence and related mortality in the United States. When used at already-observed population rates of 80% for those ≥65 years and 60% for those <65 years, face masks are associated with 69% (cloth) to 78% (medical procedure mask) reductions in cumulative COVID-19 infections and 82% (cloth) to 87% (medical procedure mask) reductions in related deaths over a 6-month timeline in the model. If cloth or medical procedure masks' source control and wearer protection efficacies are boosted about 30% each to 84% and 60% by cloth over medical procedure masking, fitters, or braces, the COVID-19 basic reproductive number of 2.5 could decrease to an effective reproductive number ≤ 1.0, and from 4.0 to ≈ 1.6 for the B.1.1.7 variant.

Text – WC 3304

Introduction:

The emergence of coronavirus disease 2019 (COVID-19) has had a substantial impact on populations globally, with efforts across governments to prevent its remarkable spread. While social distancing has been universally recommended since very early in the pandemic, recommendations for masks in the general population were adopted later in many countries (see, for example, [1]). Several factors contributed to the initial uncertainty around the potential impact of widespread use of face masks on SARS-CoV-2 transmission. An 2015 large and well-designed study on cloth face masks (the main type of mask available to the public at the time) contributed to the scientific uncertainty that these types of face coverings were effective for

preventing the transmission of respiratory diseases [2]. There were initial hypotheses that cloth

masks could give the wearer a false sense of protection and even contaminate the wearer with

accumulated viral particles, notably described in a high-profile study in the *Annals of Internal*

Medicine that was later retracted (for failure to note PCR assay values that were below the limit

of detection) [3]. Furthermore, a major concern at the beginning of the outbreak in the US was

supply, especially of high-quality masks like N95 respirators. As it became clear, however, that

the virus can spread through exhaled respiratory droplets from infected individuals without

symptoms [4], the U.S. Centers for Disease Control and Prevention (CDC) recommended masks

for general use early in the U.S. pandemic (as of April 2020, [5]). Evidence continues to show

that asymptomatic and clinically mild infections contribute substantially to SARS-CoV-2

transmission [6-9]. Together, this growing body of evidence has highlighted the importance of

prevention measures, like masking, to reduce transmission from people who are asymptomatic,

undetected, or both.[6-8].

As the COVID-19 pandemic has continued, evidence has accumulated that face mask use by the

general population can limit the spread of SARS-CoV-2. This evidence has taken three main

forms, described in order of their appearance in the literature: 1) modeling studies that suggested

that even if masks are limited in their efficacy, widespread use across the population could still

reduce the spread of the virus to a considerable degree [10, 11], 2) laboratory studies that

demonstrated masks physically block exhaled droplets and aerosols containing virus from

infected persons (source control) and also offer wearer protection [12-14], and 3)

epidemiological studies that documented lower transmission in settings where masks were used

[15-19]. In this study, we extend the model of Worby and Chang to use age-stratified social

contact patterns for the general U.S. population, and we analyzed the model both employing the

measured face mask efficacy parameters for a variety of specific types of masks and for efficacy

estimates that can act as benchmarks for evaluating these products [20].

Methods:

We adapted the transmission model (used for studying resource allocation of masks) of Worby

and Chang (2020) for face mask adoption in a hypothetical population by expanding it to the

age-stratified social contact patterns characteristic of the demographic profile of the United

States. The underlying structure of this compartmental model is described in Worby and Chang

[20], which we briefly summarize. Individuals are classified according to their disease status and

whether or not they wear a mask in public. The model is further stratified by age in 5-year age

bands. People contact each other (defined as either direct physical contact, e.g. through a

handshake or a kiss, or a proximal, two-way conversation of 3 or more words) at age-specific

daily rates estimated for the United States, as described by Mossong et al. and Prem et al. [21,

22]. Vaccination is not explicitly part of the model and has not been included in this study.

A schematic of the compartmental model is shown in Figure 1. Susceptible individuals who are

infected move into an exposed compartment and thereafter into a pre-symptomatic compartment.

Subsequently, a pre-specified proportion of these individuals moves into an asymptomatic state,

while the remainder become fully symptomatic. Pre-symptomatic, asymptomatic, and fully

symptomatic SARS-CoV-2 infected individuals all contribute to the force of infection with

varying degrees of infectiousness. All asymptomatic individuals recover, whereas a proportion of

fully symptomatic individuals do not recover and die. A fraction of asymptomatic cases is

assumed to be detected whereupon a fraction of these individuals begins to use a mask and

continue to mask thereafter. Similarly, a fraction of symptomatic cases is assumed to know they

have COVID-19, and these individuals put on a mask at the same adoption level as detected in

asymptomatic cases. Symptomatic persons and detected, asymptomatic persons who wear a

mask also change their contact rates reflective of some degree of isolation/quarantine. We do not

include specific compartments modeling quarantine per se, but rather we reduce contact rates

which accomplishes the same purpose and maintains simplicity of compartmental structure while

allowing a degree of mixing that might be anticipated among a fraction of infected individuals

who are not strictly isolating themselves. We also assumed a fraction of the general population

adopts mask usage at the outset and continues usage regardless of infection status. Other than the

aforementioned masked cases, we assumed that contact rates among age groups remain the same

when people wear a mask. A basic reproduction number (R_0) of 2.5 was assumed in the absence

of any mask use, consistent with CDC's pandemic planning scenarios [23]. We also explored the

model with a basic reproduction number of 4.0, in keeping with the estimated magnitude of the

B.1.1.7 variant [24]. The modeled time horizon was 6 months and the cumulative number of

infections and deaths were recorded. The impact of various levels of mask adoption was assessed

by calculating the relative reduction in cumulative infection and deaths, comparing cumulative

cases and deaths to the same model over the same time horizon with no mask use in the entire

population.

Masks were modeled to reduce transmission via two different mechanisms: source control

efficacy, whereby mask wearing by an infectious person reduces their likelihood of transmitting

SARS-CoV-2; and wearer protection efficacy, whereby masks protect a susceptible person from

becoming infected when exposed to an infectious person. We examined adoption of various

kinds of masks (e.g., cloth, medical procedure, N95 respirators) specifically incorporating

estimates from a recent study of source control efficacy [14]. A range of values of hypothetical

wearer protection efficacy was assumed for each kind of mask. Although it has generally been

found that wearer protectiveness coefficients are approximately half the source control values

[13, 25, 26], wearer protection efficacy was allowed to vary in the plot because it could be

greatly affected by how the mask is worn, maintained, and used. Characteristics of each mask

when worn according to manufacturers' specifications can be found in Lindsley et al. and are

shown in Table 1 [14]. We do not address the issue of mask and respirator use in healthcare

settings in this paper, as there is substantial public health guidance regarding the use of personal

protective equipment in healthcare settings [27].

Results:

Figure 2 depicts heat maps of reduced transmission and deaths over 6 months as a function of

varied source control efficacy and wearer protection efficacy. Mask wearing rates by the various

sub-populations in the model are provided in the figure caption. These rates were in line with

surveys of mask usage in the United States in May and June 2020 [28]. The colored bands of the

plots represent contours of relative reduction. Going from the bottom left corner of the figures

(source control efficacy and wearer protection efficacy both 0%, equivalent to no mask wearing

in the population) these increase in 5% increments to the right top corner (source control efficacy

and wearer protection efficacy both 100%). For example, to obtain at least a 50% reduction in

cumulative infections, source control would need to be at least 55% efficacious in limiting

transmission in the population for arbitrary wearer protection efficacy. Source control would

need to be approximately 45% effective to reduce the number of deaths by half regardless of

wearer protection efficacy.

Even with the source control and wearer protection efficacy for the types of mask that most

wearers are likely to use, such as medical procedure or cloth masks and gaiters (see Table 1),

substantial reductions in case load and death can be achieved with general population use at

stated levels. Even at lower levels of use, reductions are estimated to be substantial As source

control and wearer protection efficacy approach 100% for the masks, relative reduction in

infections also approaches 100%, even though mask adherence is far from 100%, because

transmission dips below the epidemic threshold (i.e. an effective reproduction number < 1). Our

simulations project that a 70% reduction in cumulative infections, relative to zero mask usage,

could be achieved with hypothetical combinations of wearer protection and source control

efficacies, respectively, of (0%, 65%), (25%, 50%), (40%, 35%), (50%, 25%), among many

others lying on the 70% contour curve of the left panel of Figure 2.

Figure 3 depicts the reduction in infections with different population-wide percentages of mask

use, with the assumption that mask wearer protection efficacy is half of source control efficacy

and that mask use among persons <65 years old is 70% that of persons ≥65 years old. Mask

wearing rates for detected and infected people are fixed at 90% for those ≥65 years old, and 70%

for those who are younger.   Based on the model, if 25% of the general population ≥65 years old

puts on a mask, cumulative cases after 6 months are reduced by 23% (N95), 14% (medical

procedure), 12% (cloth), 12% (gaiter), and 9% (bandana). If mask adoption is 50% for the

general population ≥65 years old, projected reductions in cases are 57% (N95), 32% (medical

procedure), 28% (cloth), 28% (gaiter), and 20% (bandana). If mask adoption is 75% for ≥65

years old, projected reductions in cases are 95% (N95), 65% (medical procedure), 55% (cloth),

54% (gaiter), and 35% (bandana). Note that even with 0% mask use for the susceptible

population (horizontal axis), , there is still a small measure of infection control because of mask

adoption among detected infected people.

We estimated the incidence rate ratios (IRR) for new infections among mask wearers relative to

non-mask wearers over the course of 6 months, for different types of mask (Table 2). These

estimates reflect the impact of mask wearing on an individual wearer, whereas all of the other

analyses in this paper are focused on the population-level impact. The IRR at a given point in

time is the ratio of the number of new infections per capita among the mask wearing population

to the corresponding number among the non-mask wearing population. This assumes equal

mixing of masked and non-masked individuals – modeling the tendency for those populations to

self-segregate would tend to decrease these IRR values. As expected, the greater the mask

efficacy, the greater the difference in new infection rates as measured by the IRR. After 6

months, new infections are projected to occur at around half the rate among mask wearers

compared to those not wearing N95 respirators, whereas in a scenario where medical procedure

masks are worn, infections among mask wearers occur at around a 32% lower rate.

We evaluated the impact of face mask usage rates and efficacy parameters on the effective

reproduction number for $R_0 = 2.5$ and $R_0 = 4.0$, to represent the potential impact of novel

variants (e.g., B.1.1.7) (Figure 4) [24].   Note that warmer colors corresponding to higher

effective reproduction numbers are visible in the lower left-hand corner of the right panel but

less so in the left panel. As we approach 100% source control and wearer protection efficiencies,

masks reduce effective reproduction number < 1 for the low R_0 scenario, but not for the high R_0

scenario, given the same wearing percentages used to generate Figure 2. For example, when the

baseline $R_0 = 2.5$, an effective reproduction number of 1 is achieved by a hypothetical mask with

source control and wearer protection efficacies of 84% and 60%, respectively. However, these

same efficacies would result in an effective reproduction number of 1.6 when the baseline $R_0 =$

4.0. Those efficacies for masks are achievable with common cloth masks and medical procedure

masks if they are doubled up, if the cloth masks have filter inserts, or if either type of mask is

overfit with a fitter or brace to ensure a tighter fit [29-31]. If source control efficacy is 96% and

wearer protection efficacy is > 70% (in line with efficacies for N95 respirators) then the effective

reproduction numbers < 1.0 ($R_0 = 2.5$) and = 1.5 ($R_0 = 4.0$). Similarly, adoption of medical

procedure masks (source control efficacy 56%, wearer protection efficacy 28%), results in

effective reproduction numbers of 1.30 ($R_0 = 2.5$) and 2.07 ($R_0 = 4.0$).

Discussion:

Our results highlight the potential for substantial reduction in SARS-CoV-2 transmission, even

with moderately effective masks, when they are worn consistently correctly (over the chin and

covering nose and mouth) and/or per manufacturers' specifications by a large portion of the

population. These findings underscore the potential impact of population-wide measures that can

control transmission from infected individuals who do not have symptoms, both pre-

symptomatic individuals who are infectious prior to developing symptoms and individuals who

never experience symptoms. By extending the Worby and Chang model, we evaluated the

impact of different face mask use by age and highlight the need for wide adoption of these

interventions. Pairing this modeling framework with laboratory-derived parameters for source

control efficacy of different types of face masks helps to more accurately compare the relative

efficacy of each mask type as an intervention. Even with more specific source control

parameterization, the results are generally consistent with previous modeling studies [10, 11]:

face masks with realistic source control efficacy can reduce transmission substantially, and

widespread adoption can mitigate transmission at the population level. Furthermore, if the most

common types of face mask – cloth and medical procedure masks – can be enhanced with more

recent recommendations to improve fit around the nose and mouth, such as braces, elastic fitters,

or even double masking, those substantial reductions can be improved upon.

Our study and several others suggest that the magnitude of reduction in SARS-CoV-2

transmission increases non-linearly with increased mask usage. The reasons for the non-linear

multiplier effect are several, at least including potential epidemiological, immunological, and

behavioral mechanisms [17, 27, 31, 32]. Non-linear terms are inherent in the mathematical

mechanism of transmission reduction, given that masks act as both source control on the infected

and personal protection on the susceptible, terms which are multiplied together in the

transmission equations. This can be seen in the curvature of the line graphs of Figure 3 as mask

usage increases (diminishing returns can be seen as mask usage increases towards 100% for the

N95 respirators, however). Furthermore, it is hypothesized that there are non-linear effects

inherent in the pathogenesis of SARS-CoV-2 infection, in that masks reduce the initial viral

exposure even if a wearer becomes infected despite the mask, decreasing the severity of

infection, reducing viral load and shedding, and increasing the asymptomatic ratio [17, 32, 33]. If

this hypothesis is substantiated and we ignore complications arising from a higher asymptomatic

rate (i.e., more challenges with case identification), then there are potentially several non-linear

terms describing how the reproduction number decreases with mask efficacy and use. Lastly,

analysis of data on behavioral correlates of face mask use shows that people wear face masks

more often when they see others do so, even when they already intended to wear a mask [28]. If

changes in behavior were modeled, this would add another favorable non-linear term to the

impact of mask wearing.

The pandemic literature does contain a minority of reports that do not confirm the efficacy of

masks, although these studies have some important limitations. In particular, commentaries have

been written about the methodological limitations of a recent publication by Bundgaard et al. that

appears to question the efficacy of face masks [34]. [35, 36]. Specifically, the study was only

powered to test if the wearer protection efficacy of medical procedure masks (referred to as

"surgical masks" in Bundgaard et al.) was >50% and was not designed to measure their effect as

source control (because it was estimated only 5% of the population were wearing masks at the

time of the study). The Bundgaard et al. results were underpowered to detect wearer protection

efficacies of medical procedure and cloth masks. This is similar to another randomized

controlled trial (RCT) of cloth face masks as wearer protection against influenza virus infection

among healthcare workers by MacIntyre et al. [2]: the study was designed to evaluate only the

wearer protection effectiveness, not the source control effectiveness. Critically, the MacIntyre et

al. study did not compare cloth masks to no mask, only to masks of the health workers' choosing,

potentially including medical procedure masks. Hence, this RCT *in a healthcare setting* did not

have the negative control of not wearing a mask to help inform definitive conclusions about the

efficacy of cloth face masks for the general population in non-healthcare settings. In fact, a

follow-up study by MacIntyre et al. in 2020 found that healthcare workers whose cloth masks

were laundered by the hospital were protected as well as those who wore medical masks [37].

Also, recent results from an epidemiological study [38] analyzing population level mask

mandates where masks are more widely used are much more positive regarding the effectiveness

of masks.

Limitations:

Despite widespread usage of masks and other mitigation strategies [39], transmission of SARS-

CoV-2 remains inadequately controlled in the United States. There are many potential reasons

why surveillance data and ecologic field studies might not show the magnitude of reduction in

infections due to increasing mask usage predicted here. The parameters used in the models

developed here might need to be better calibrated to match local transmission probabilities when

individuals contact one another (either through direct physical contact, e.g. through a handshake

or kiss, or a proximal, two-way conversation consisting of 3 or more words). Also, surveys

indicating mask usage in the population may have overestimated adherence over time or the

proper use or maintenance of masks. We model mask use as a set of parameters that can vary by

age, but not by other societal subgroups, and our age groups were only divided into ≥65 years

and <65 years. Furthermore, our model does not distinguish between differing contact rates

within relevant populations such as schools, workplace, and households, but instead uses U.S.-

national estimates for contact rates.

The source data for mask efficacy used in these models were derived from controlled laboratory

simulations and not from human experiments. Measurements by other groups of filtration

efficiency using actual human volunteers tend to show more variation, and in some cases the

efficacies are lower than those reported here [40, 41].

Other limitations of the study are that mask usage is not assumed to vary over time, although it is

likely that consistent and correct mask use may increase or decrease over time as individuals

change their behaviors. Thus, we model homogeneous and unchanging mask use in a limited

number of subgroups vs. the reality that mask wearing is heterogeneous according to mask type,

sub-population, maintenance and proper use, and many other time-varying characteristics. This

may result in over-estimation of the impact of face masks on the pandemic. If so, even higher

mask uptake would be necessary to achieve substantial reductions in cases than is indicated here.

Although the post-holiday 2020-2021 surge in cases seems large given a fairly high rate of mask

usage, we have no solid counterfactual information for comparison [12], i.e. we do not know

what the results would have been with no mask usage.

Conclusions:

Modeling studies, including this analysis, have estimated how face masks can reduce

transmission of SARS-CoV-2 and make a major impact at the population level, even with

varying levels of adherence and effectiveness of masks. Multiple public health interventions are

needed to reduce the transmission of SARS-CoV-2 and, as our analysis shows, robust use of face

masks is an important contributor. Face masks of various materials have the potential to

substantially reduce transmission in the SARS-CoV-2 pandemic, depending on the type of mask

and the percentage adoption in the population. Public outreach and policies encouraging mask

wearing, especially highly efficacious masks, need to be encouraged along with other prevention

strategies (e.g., social distancing, hand washing, and vaccination). In fact, this study suggests that

the current, imperfect use of masks has likely already reduced both cases and deaths.

Author Bios:

Brian Gurbaxani is a computational biologist in the CDC's Office of Science, where he works

with universities and academic partners to supply engineering, data modernization, and modeling

solutions to the CDC community. A systems engineer, immunologist, and mathematical modeler

by training, he co-chairs the CDC's Infectious Disease Modelers Community of Practice. Brian

is also an adjunct professor of Industrial and Systems Engineering and Electrical and Computer

Engineering at the Georgia Institute of Technology.

Andrew Hill leads the DM/Statistics Team in the Data Management, Statistics, and Evaluation

Branch of the Division of Tuberculosis Elimination. He has worked on theoretical foundations of

infectious disease models, with applications to TB, pertussis, and Ebola, as well as methods to

estimate the prevalence of latent TB infection and performance of diagnostic tests. He has an

adjunct appointment in the Biostatistics and Bioinformatics Department, Rollins School of

Public Health, Emory University.

Supplement:

Methods

Transmission of SARS-CoV-2 is modeled by a system of ordinary differential equations (ODE)

and compartments corresponding to age, disease status, and mask-wearing status. Compartments

comprise susceptible (S), exposed (E), pre-symptomatic (P), asymptomatic and undetected (A_u),

asymptomatic and detected (A_d), symptomatic (I), recovered (R), and deceased (D). The total

population is $N = S + E + P + A_u + A_d + I + R$. Initially, $N = 100,000$. Each of these compartments

is further stratified by age (16 age groups from the POLYMOD study) and mask-wearing status

(yes/no). Thus, each disease compartment is represented by a 16×2 matrix, with entries

corresponding to the number of individuals of that particular disease status in age group $i =$

$1, ..., 16$ and with mask status $j = 0$ (no mask), 1 (mask). In matrix form, the ODE system is:

$$\dot{S} = -q \left\{ M((I + p_{\text{rel inf}} A_d) \cdot [1_{16} \; r1_{16}] + p_{\text{rel inf}} (P + A_u))/N \begin{bmatrix} 1 & 1-w \\ 1-s & (1-w)(1-s) \end{bmatrix} \right\} \cdot S$$

$$\dot{E} = q \left\{ M((I + p_{\text{rel inf}} A_d) \cdot [1_{16} \; r1_{16}] + p_{\text{rel inf}} (P + A_u))/N \begin{bmatrix} 1 & 1-w \\ 1-s & (1-w)(1-s) \end{bmatrix} \right\} \cdot S$$
$$\qquad - \nu_E E$$

$$\dot{P} = \nu_E E - \nu_P P$$

$$\dot{A}_d = p_{\text{asym}} p_{\text{detect}} \nu_P \left(P + (p_{\text{inf mask use}} \cdot P) \begin{bmatrix} -1 & 1 \\ 0 & 0 \end{bmatrix} \right) - \nu_A A_d$$

$$\dot{A}_u = p_{\text{asym}} (1 - p_{\text{detect}}) \nu_P P - \nu_A A_u$$

$$\dot{I} = (1 - p_{\text{asym}}) \nu_P \left(P + (p_{\text{know}} p_{\text{inf mask use}} \cdot P) \begin{bmatrix} -1 & 1 \\ 0 & 0 \end{bmatrix} \right) - \nu_I I$$

$$\dot{R} = \nu_A (A_d + A_u) + (1 - p_{\text{death}}) \nu_I I$$

Dot superscript denotes derivative with respect to time; central dot $\cdot$ indicates pointwise

multiplication of matrices of the same dimension, or of the columns of a matrix by a vector of

the same dimension.

Compartment durations are specified by a rate ν_J, where J is the compartment. Average duration

in a compartment is $1/\nu_J$. These rates model the durations of days exposed (2 days), pre-

symptomatic (4 days), asymptomatic (9 days), and symptomatic (9 days). Relative infectiousness

of pre-symptomatic and asymptomatic persons compared to symptomatic persons is $p_{\text{rel inf}} = 0.75$.

Detection probability of an asymptomatic case is $p_{\text{detect}} = 0.05$ and the proportion of

asymptomatic infections is $p_{asym} = 0.40$. The risk of death for symptomatic individuals was

inferred from age-specific infection fatality ratios (IFR) via the equation CFR = IFR/(1 − p_{asym}),

where CFR denotes the case fatality ratio. IFRs are 0.00003 for ages 0-19 years, 0.0002 ages 20-

49, 0.005 ages 50-69, 0.054 ages 70 and older. These parameters are based on the September

2020 estimates included in the CDC Pandemic Planning Scenario #5 [23]. We further assume

that 20% of symptomatic individuals know that that they are sick with SARS-CoV-2 and we

denote this fraction by p_{know}. These people put on a mask.

POLYMOD daily contact rates were obtained from the study by Prem *et al.* [21]. The raw matrix

of contact rates was adjusted in the usual fashion to maintain balance (numbers of contacts of

age group i with age group j same as that of j with i). The raw matrix C is transformed to C' by

$$C'_{ij} = \tfrac{1}{2}(C_{ij} + C_{ji}N_j/N_i)$$

345   where N_i is the population size of age group i. Age distribution of the population was based on

346   American Community Survey (ACS) estimates for the U.S. population [42]. Matrix C' is, in

347   turn, transformed to give the symmetric matrix M in the ODEs by

$$M_{ij} = \tfrac{N}{2}(C_{ij}/N_j + C_{ji}/N_i) = C'_{ij}/(N_j/N)$$

349   In this formulation, a typical term in the force of infection (FoI) arising from an age-stratified

350   infectious compartment $J = P, A_d, A_u, I$ of a given mask status is

$$(MJ)_i/N = \sum_{k=1}^{m} M_{ik}J_k/N = \sum_{k=1}^{m} C'_{ik}J_k/N_k$$

where $m = 16$ is the number of POLYMOD age groups corresponding to 5-year age bands

ranging from younger than 5 years old to 70-75 years old, with the oldest age group comprising

persons 75 years and older. The FoI is further stratified in the ODEs above depending on mask

status. This is implemented by the 2×2 matrix appearing in the differential equations for S and

E. This matrix governs reductions in the FoI according to source control efficacy (sce, or s for

brevity) and wearer protection efficiency (wpe, or w) conferred by the mask type. These combine

in four ways depending on the mask status of the infector and infectee (e.g., $1 - $ wpe and $1 - $ sce

multiply together in the case of transmission by mask wearers to mask wearers). We further

assume that symptomatic and detected, asymptomatic people who wear a mask have a lower,

daily rate of contact. As contact rates in compartmental models apply to susceptible, not

infectious, individuals, we model this as a reduction in infectiousness by a proportion r for both

symptomatic and detected, asymptomatic mask-wearers. Specifically, if subscript i indexes age

group and superscripts 'none' and 'mask' denote no mask and mask wearing, respectively,

expanding the matrix formulation of the ODEs for susceptible individuals gives

$$\dot{S}_i^{none} = -q \sum_{k=1}^{m} M_{ik}(K_k^{none} + (1 - \text{sce})K_k^{mask}) \times S_i^{none}/N$$

$$\dot{S}_i^{mask} = -q(1 - \text{wpe}) \sum_{k=1}^{m} M_{ik}(K_k^{none} + (1 - \text{sce})K_k^{mask}) \times S_i^{mask}/N$$

where $K^{\text{none}} = I^{\text{none}} + p_{\text{rel inf}}(P^{\text{none}} + A_d{}^{\text{none}} + A_u{}^{\text{none}})$ and

$K^{\text{mask}} = r\,I^{\text{mask}} + p_{\text{rel inf}}(P^{\text{mask}} + r\,A_d{}^{\text{mask}} + A_u{}^{\text{mask}})$.

The age-specific vector $p_{\text{inf mask use}}$ (in the set of 7 ODEs specified at the beginning of this

supplement) specifies the proportion of symptomatic and detected asymptomatic people who don

a mask upon learning they are infectious. The corresponding proportion for symptomatic

individuals is $p_{\text{know}} \times p_{\text{inf mask use}}$. The 2×2 matrix appearing in the differential equations for A_d

and I governs the adoption of masks by asymptomatic individuals when they are detected (the

first column corresponds to no mask, the second to mask wearing). In simulations, we assumed

that individuals aged 65 years and older adopted masks at one proportion and younger than 65

years at another, lower, proportion (but this can be changed by the user). Expanding the matrix

formulation of the ODEs for detected asymptomatic individuals gives

$$\begin{aligned}
\dot{A}_{d,i}^{\text{none}} &= p_{\text{asym}}\,p_{\text{detect}}\,\nu_P(1 - p_{\text{inf mask use},i})P_i^{\text{none}} - \nu_A\,A_{d,i}^{\text{none}} \\
\dot{A}_{d,i}^{\text{mask}} &= p_{\text{asym}}\,p_{\text{detect}}\,\nu_P(P_i^{\text{mask}} + p_{\text{inf mask use},i}P_i^{\text{none}}) - \nu_A\,A_{d,i}^{\text{mask}}
\end{aligned}$$

It is assumed that a proportion of the general population (susceptible individuals) wear a mask at

the outset and keep it on at all times (or at least when mixing in the population). This proportion

can vary by age. We assume that in the general population, 80% of those aged 65 and older and

60% of the rest, wear a mask (and keep it on indefinitely).

To seed the epidemic, we arbitrarily assumed that there were 10 detected, asymptomatic non-

masked individuals in each age group at the outset. Time units were expressed in days. The

model was run for 6 months (183 days) with a timestep of 0.25 days using a Runge-Kutta solver

in R v.3.6.3 [43] using the package 'deSolve' [44].

The FoI was calibrated to yield a basic reproduction number $R_0 = 2.5$ for the sub-model without

mask usage. This yielded the parameter $q = 0.01429$, which represents the probability of a

symptomatic infectious person infecting a susceptible person upon contact between them. The

reproduction number was calculated as the dominant eigenvalue of the next-generation matrix

(NGM) using the method of van den Driessche and Watmough [45]. Computation was facilitated

by the R package 'blockmatrix' [46] owing to the sparseness of the matrices involved. Details of

this calculation are described further below.

Calculation of R_0

Following [45], we construct matrices F, describing rates at which infectious individuals produce

new infections, and V, consisting of all other rates, whose inverse describes average durations in

compartments. The ith row and jth column of these matrices is the partial derivative of the right-

hand side of the differential equation for compartment i with respect to compartment j, evaluated

at the disease-free equilibrium (DFE). Only the 5 infected compartment types are considered,

namely, E, P, A_d, A_u, I, enumerated by age group and mask status. The basic reproduction

number R_0 is given by the dominant eigenvalue of the NGM $F V^{-1}$.

Matrices F and V are of dimension 160×160 (2 mask statuses $\times$ 16 age groups $\times$ 5 relevant

compartment types). However, as new infections only arise from the E compartments, via the

previously described FoI, matrix F is sparse. So too is V, as a lot of its sub-blocks are zero or

diagonal matrices. Hence, we can construct these matrices in block form. We use the Kronecker

product of matrices, which we denote by $\otimes$.

The DFE depends on the initial age-specific proportions, $p_{\text{susc mask use}}$, of the general, susceptible

population wearing a mask. Multiplying the ACS age group proportions pointwise by $p_{\text{susc mask use}}$

and $1 - p_{\text{susc mask use}}$ gives the age-specific proportions of the population with and without masks,

respectively. These are multiplied by the hypothetical total population size $N = 100,000$ to obtain

numbers in each stratum.

Vectorizing the 16×2 matrices in the ODEs by stacking columns into a single 32×1 column

vector, we have the following constituent matrices for calculating R_0:

$$F_1 = \begin{bmatrix} 1 \\ 0 \\ 0 \\ 0 \\ 0 \end{bmatrix}_{5\times1} \otimes \left\{ \left(\left\{ \left(\underbrace{\begin{bmatrix} 1 \\ 1-w \end{bmatrix}}_{2\times1} \otimes \underbrace{[0\ p_{\text{ri}}\ p_{\text{ri}}\ p_{\text{ri}}\ 1]}_{1\times5} \otimes \underbrace{[1\ 1-s] \cdot \underbrace{G}_{2\times10}}_{1\times2} \right\} \otimes \underbrace{(M \cdot p_{\text{ACS}})}_{16\times16} \right) \cdot \underbrace{\begin{bmatrix} 1_{16} - p_{\text{smu}} \\ p_{\text{smu}} \end{bmatrix}}_{32\times1} \right) \right\}$$

$$G = \begin{bmatrix} 1_5^{\mathsf{T}} & r & 1_3^{\mathsf{T}} & r \\ 1_5^{\mathsf{T}} & r & 1_3^{\mathsf{T}} & r \end{bmatrix}$$

For brevity, $p_{\text{r.i.}}$ denotes $p_{\text{rel inf}}$ above, p_{ACS} is the ACS population age distribution, $p_{\text{s.m.u.}}$ denotes

$p_{\text{susc mask use}}$ above, w denotes WPE, s denotes SCE, $\mathbf{1}_n$ is the $n\times1$ vector of 1's, and $\cdot$ represents

pointwise multiplication by column. Matrix M is the POLYMOD-derived contact matrix

described earlier. It follows from the definition of Kronecker product that F_1 is 160×160. The

order of entries in row or column vectors of length 5 corresponds to the compartment types $E, P,$

A_d, A_u, I. Thus, the 5×1 vector on the left represents new infections only arising from

compartments of type E (component 1) and not from P, A_d, A_u, I (components 2 to 5) and its

occurrence renders F_1 sparse. The 1×5 row vector has components 2-4 as $p_{\text{rel inf}}$, indicating the

relative infectiousness of presymptomatic and detected and undetected asymptomatic individuals

(P, A_d, A_u) compared to symptomatic individuals I (component 5). Row and column vectors of

length 2 correspond to mask efficacies. The vector p_{ACS} represents the population age-

distribution and the 32×1 vector on the right denotes the age-specific general population mask

wearing proportions.

The matrix F is given by $F = qF_1$, where q is the calibration parameter representing the

probability of symptomatic infectious persons infecting susceptible persons upon contact

between them.

Matrix V may also be expressed in block form as:

$$
V = \begin{bmatrix}
V_{EE} & 0 & 0 & 0 & 0 \\
V_{PE} & V_{PP} & 0 & 0 & 0 \\
0 & V_{A_dP} & V_{A_dA_d} & 0 & 0 \\
0 & V_{A_uP} & 0 & V_{A_uA_u} & 0 \\
0 & V_{IP} & 0 & 0 & V_{II}
\end{bmatrix}
$$

440   where each block is a 32×32 matrix. Theory guarantees V is invertible. As with F, the order of

441   the component types in block rows and columns here is E, P, A_d, A_u, I. The nonzero blocks are as

442   follows, with parameter notation as given earlier, and I_n denoting the $n \times n$ identity matrix:

$$
\begin{aligned}
V_{EE} &= \nu_E I_{32} \\
V_{PE} &= -\nu_E I_{32} \\
V_{PP} &= \nu_P I_{32} \\
V_{A_dP} &= -\nu_P\, p_{\text{detect}}\, p_{\text{asym}} B_A \\
\text{where } B_A &= \begin{bmatrix} \text{diag}(1 - p_{\text{inf mask use}}) & 0 \\ \text{diag}(p_{\text{inf mask use}}) & I_{16} \end{bmatrix} \ (16 \times 16 \text{ blocks}) \\
V_{A_dA_d} &= \nu_A I_{32} \\
V_{A_uP} &= -\nu_P\,(1 - p_{\text{detect}}) p_{\text{asym}} I_{32} \\
V_{A_uA_u} &= \nu_A I_{32} \\
V_{IP} &= -\nu_P\,(1 - p_{\text{asym}}) B_I \\
\text{where } B_I &= \begin{bmatrix} \text{diag}(1 - p_{\text{know}} p_{\text{inf mask use}}) & 0 \\ p_{\text{know}}\text{diag}(p_{\text{inf mask use}}) & I_{16} \end{bmatrix} \ (16 \times 16 \text{ blocks}) \\
V_{II} &= \nu_I I_{32}
\end{aligned}
$$

Blocks V_{XX} on the leading diagonal correspond to outflows from compartment type X. Off-

diagonal blocks V_{XY} correspond to inflows from compartment type Y to compartment type X. The

B matrices correspond to the adoption of mask use (change of mask status) upon asymptomatic

detection/symptomatic awareness, according to the age-specific proportion ($p_{\text{inf mask use}}$) who do

so. Denoting the dominant eigenvalue of a matrix by ρ, we have

$R_0 = \rho(F\,V^{-1}) = q \times \rho(F_1 V^{-1}).$

Setting baseline $R_0 = 2.5$ (no mask use), we calibrate $q = 2.5 \div \rho(F_1 V^{-1})$.

Computation of symptomatic and asymptomatic detection rates

The percentage of symptomatic and asymptomatic SARS-CoV-2 cases that are detected are not

established numbers, but they are suspected to be low given the general detection rate of 9.1%

[23] . Both can be estimated with a simple Bayesian calculation, however, given the general

detection rate (P(case) in the equation below), the asymptomatic rate of infections of 0.4 [23],

and the probability that detected cases are and remain asymptomatic (0.2) or symptomatic (0.8)

[47]. For example, the probability that you become a detected case (e.g. through contact tracing

efforts) given you are asymptomatic is given below

P(case|asymptomatic) = P(asymptomatic|case) P(case)/P(asymptomatic

The simple calculation yields a 5% detection rate for asymptomatic individuals and a 20%

detection rate for those with symptoms. The 20% figure appears to be in line with

epidemiological estimates as well [48].

References:

1.   Brosseau, L.M., and Sietsema, M., *Commentary: Masks-For-All for Covid-19 Not Based on Sound*
Data (University of Minnesota). 2020.
2.   MacIntyre, C.R., et al., *A cluster randomised trial of cloth masks compared with medical masks in*
healthcare workers. BMJ Open, 2015. **5**(4): p. e006577.
3.   Bae, S., et al., *Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled*
Comparison in 4 Patients. Ann Intern Med, 2020. **173**(1): p. W22-w23.
4.   Bai, Y., et al., *Presumed Asymptomatic Carrier Transmission of COVID-19.* JAMA, 2020. **323**(14):
p. 1406-1407.

5.　Centers for Disease Control and Prevention. *Considerations for Wearing Masks*. 2020 December
18, 2020; Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-
sick/cloth-face-cover.html.
6.　Byambasuren, O., et al., *Estimating the extent of asymptomatic COVID-19 and its potential for*
community transmission: systematic review and meta-analysis. JAMMI, 2020.
7.　Poletti, P., et al., *Probability of symptoms and critical disease after SARS-CoV-2 infection.* arXiv.
8.　Oran, D.P. and E.J. Topol, *Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative*
Review. Ann Intern Med, 2020. **173**(5): p. 362-367.
9.　Johansson, M.A., et al., *SARS-CoV-2 Transmission From People Without COVID-19 Symptoms.*
JAMA Network Open, 2021. **4**(1): p. e2035057-e2035057.
10.　Ngonghala, C.N., et al., *Mathematical assessment of the impact of non-pharmaceutical*
interventions on curtailing the 2019 novel Coronavirus. Math Biosci, 2020. **325**: p. 108364.
11.　Eikenberry, S.E., et al., *To mask or not to mask: Modeling the potential for face mask use by the*
general public to curtail the COVID-19 pandemic. Infect Dis Model, 2020. **5**: p. 293-308.
12.　Fisher, K.A., et al., *Factors Associated with Cloth Face Covering Use Among Adults During the*
COVID-19 Pandemic - United States, April and May 2020. MMWR Morb Mortal Wkly Rep, 2020.
69(28): p. 933-937.
13.　Konda, A., et al., *Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth*
Masks. ACS Nano, 2020. **14**(5): p. 6339-6347.
14.　Lindsley, W.G., et al., *Efficacy of face masks, neck gaiters and face shields for reducing the*
expulsion of simulated cough-generated aerosols. Aerosol Science and Technology, 2020: p. 1-
12.
15.　Payne, D.C., et al., *SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy*
Service Members - USS Theodore Roosevelt, April 2020. MMWR Morb Mortal Wkly Rep, 2020.
69(23): p. 714-721.
16.　Hendrix, M.J., et al., *Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After*
Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020.
MMWR Morb Mortal Wkly Rep, 2020. **69**(28): p. 930-932.
17.　Ing, A.J., C. Cocks, and J.P. Green, *COVID-19: in the footsteps of Ernest Shackleton.* Thorax, 2020.
75(8): p. 693-694.
18.　Lyu, W. and G.L. Wehby, *Community Use Of Face Masks And COVID-19: Evidence From A Natural*
Experiment Of State Mandates In The US. Health Aff (Millwood), 2020. **39**(8): p. 1419-1425.
19.　Brooks, J.T. and J.C. Butler, *Effectiveness of Mask Wearing to Control Community Spread of*
SARS-CoV-2. Jama, 2021. **325**(10): p. 998-999.
20.　Worby, C.J. and H.H. Chang, *Face mask use in the general population and optimal resource*
allocation during the COVID-19 pandemic. Nat Commun, 2020. **11**(1): p. 4049.
21.　Prem, K., A.R. Cook, and M. Jit, *Projecting social contact matrices in 152 countries using contact*
surveys and demographic data. PLoS Comput Biol, 2017. **13**(9): p. e1005697.
22.　Mossong, J., et al., *Social contacts and mixing patterns relevant to the spread of infectious*
diseases. PLoS medicine, 2008. **5**(3): p. e74-e74.
23.　Centers for Disease Control and Prevention. *COVID-19 Pandemic Planning Scenarios*. 2020
September 10, 2020; Available from: https://www.cdc.gov/coronavirus/2019-
ncov/hcp/planning-scenarios.html.
24.　Volz, E., et al., *Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking*
epidemiological and genetic data. 2021: p. 2020.12.30.20249034.
25.　Chan, J.F., et al., *Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a*
Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19). Clin Infect Dis, 2020.
71(16): p. 2139-2149.

26. Ueki, H., et al., *Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2.*
mSphere, 2020. **5**(5).
27. Centers for Disease Control and Prevention. *Interim Infection Prevention and Control*
Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19)
Pandemic. 2020 December 14, 2020; Available from: Interim Infection Prevention and Control
Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19)
Pandemic.
28. Barile, J.P., et al., *Theory-based Behavioral Predictors of Self-reported Use of Face Coverings in*
Public Settings during the COVID-19 Pandemic in the United States. Ann Behav Med, 2020.
29. Gandhi, M. and L.C. Marr, *Uniting Infectious Disease and Physical Science Principles on the*
Importance of Face Masks for COVID-19. Med, 2021. **2**(1): p. 29-32.
30. Rothamer, D.A., et al., *Strategies to minimize SARS-CoV-2 transmission in classroom settings:*
Combined impacts of ventilation and mask effective filtration efficiency. 2021: p.
2020.12.31.20249101.
31. Brooks, J.T., et al., *Maximizing Fit for Cloth and Medical Procedure Masks to Improve*
Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021. MMWR Morb Mortal
Wkly Rep, 2021. **70**(7): p. 254-257.
32. Gandhi, M. and G.W. Rutherford, *Facial Masking for Covid-19 - Potential for "Variolation" as We*
Await a Vaccine. N Engl J Med, 2020. **383**(18): p. e101.
33. Sims, M.D., et al., *COVID-19 seropositivity and asymptomatic rates in healthcare workers are*
associated with job function and masking. Clin Infect Dis, 2020.
34. Bundgaard, H., et al., *Effectiveness of Adding a Mask Recommendation to Other Public Health*
Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled
Trial. Ann Intern Med, 2020.
35. Laine, C., S.N. Goodman, and E. Guallar, *The Role of Masks in Mitigating the SARS-CoV-2*
Pandemic: Another Piece of the Puzzle. Ann Intern Med, 2020.
36. Frieden, T.R. and S. Cash-Goldwasser, *Of Masks and Methods.* Ann Intern Med, 2020.
37. MacIntyre, C.R., et al., *Contamination and washing of cloth masks and risk of infection among*
hospital health workers in Vietnam: a post hoc analysis of a randomised controlled trial. BMJ
Open, 2020. **10**(9): p. e042045.
38. Van Dyke, M.E., et al., *Trends in County-Level COVID-19 Incidence in Counties With and Without*
a Mask Mandate - Kansas, June 1-August 23, 2020. MMWR Morb Mortal Wkly Rep, 2020.
69(47): p. 1777-1781.
39. Hutchins, H.J., et al., *COVID-19 Mitigation Behaviors by Age Group - United States, April-June*
2020. MMWR Morb Mortal Wkly Rep, 2020. **69**(43): p. 1584-1590.
40. Clapp, P.W., et al., *Evaluation of Cloth Masks and Modified Procedure Masks as Personal*
Protective Equipment for the Public During the COVID-19 Pandemic. JAMA Intern Med, 2021.
181(4): p. 463-469.
41. Mueller, A.V., et al., *Quantitative Method for Comparative Assessment of Particle Removal*
Efficiency of Fabric Masks as Alternatives to Standard Surgical Masks for PPE. Matter, 2020. **3**(3):
p. 950-962.
42. U.S. Census Bureau, *American Community Survey*, T. S0101, Editor. 2019, U.S. Census Bureau:
data.census.gov.
43. R Core Development Team, *A language and environment for statistical computing.*, R.F.f.S.
Computing., Editor. 2020.
44. Soetaert, K., T. Petzoldt, and R.W. Setzer, *Solving Differential Equations in R: Package deSolve.*
2010, 2010. **33**(9): p. 25 %J Journal of Statistical Software.

45. van den Driessche, P. and J. Watmough, *Reproduction numbers and sub-threshold endemic*
equilibria for compartmental models of disease transmission. Math Biosci, 2002. **180**: p. 29-48.
46. Cordano, E., *blockmatrix: Tools to solve algebraic systems with partitioned matrices. R package*
version 1.0. 2014.
47. Buitrago-Garcia, D., et al., *Occurrence and transmission potential of asymptomatic and*
presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLOS
Medicine, 2020. **17**(9): p. e1003346.
48. Smith, L.E., et al., *Adherence to the test, trace, and isolate system in the UK: results from 37*
nationally representative surveys. BMJ, 2021. **372**: p. n608.

Address for Correspondence:

578 Brian M. Gurbaxani, PhD. Address: 1600 Clifton Rd NE, Atlanta, GA 30333. Email:

579 buw8@cdc.gov.

580 Andrew N. Hill, PhD. Address: 1600 Clifton Rd NE, Atlanta, GA 30333. Email: fyu7@cdc.gov.

Tables

Table 1: Parameter values used in the simulation

Parameter	Value [reference]
Percentage of uninfected persons wearing masks at the outset	Varies by scenario
Mask efficacy as source control:	[14]
N95 respirator	96%
Medical procedure mask	56%
Cloth mask	49%
Gaiter	48%
Bandana	33%

Percentage of asymptomatic detected cases and symptomatic cases who have been detected as COVID-19 cases who adopt mask use	<65 years old: 70% ≥65 years old: 90%
Percentage of symptomatic cases who know they have COVID-19	20% (see Supplement)
Average duration of incubation period	6 days [23]
Average duration of asymptomatic and symptomatic periods	9 days [23]
Relative infectiousness of asymptomatic cases/symptomatic cases	75% [23]
Percentage of infections that are asymptomatic	40% [23]
Probability of detecting asymptomatic case	5% (see Supplement)
Infection Fatality Ratio (IFR)	Ages 0–19: 0.00003 Ages 20–29: 0.0002 Ages 50–69: 0.005 Ages 70+: 0.054 [23]
Reduction in contact rate for symptomatic and detected asymptomatic persons wearing a mask	50%
Risk of death for symptomatic cases	See Supplement for calculation

Table 2: Incidence rate ratios (IRR) at 2-month intervals of new infections among masked vs.

non-masked population. Each row represents a scenario in which all mask-wearing individuals

are assumed to wear the specified type of mask. Wearer protection efficacy is assumed to be half

of source control efficacy. It assumes 60% of the susceptible population <65 years old are

wearing masks, 80% of those ≥65 years old wear masks, and both rates increase 10% for both

detected and infected persons (whether symptomatic or asymptomatic).

	2 months	4 months	6 months
Type of Mask		IRR	
N95 respirator	0.47	0.48	0.48
Medical procedure	0.66	0.67	0.69
Cloth Mask	0.69	0.70	0.72
Gaiter	0.69	0.71	0.74
Bandana	0.76	0.78	0.81

IRR=Incidence rate ratio

Figure Legends

Figure 1: Schematic of compartmental model. Compartments are susceptible (S, green),

exposed (E, yellow), infectious compartments (pre-symptomatic P, asymptomatic and detected

A_d, asymptomatic and undetected A_u, symptomatic I, pink), recovered (R, gray), and died (D,

gray). Superscript 'n' denotes no mask, and 'm' denotes mask.

Figure 2: Heat maps of the percentage reduction in cumulative infections at the end of 1 year

relative to no mask use in the population. Assumes 60% of the susceptible population <65 years

old are wearing masks, 80% of those ≥65 years old wear masks, and both rates increase 10% for

detectably infected persons (whether symptomatic or asymptomatic). The simulation posits that

20% of symptomatic infected people and 5% of asymptomatic infected individuals have been

detected by screening and are known to be carrying SARS-CoV-2. Mask efficacy parameters for

source control and wearer protection increase along the vertical and horizontal axes, respectively.

Reductions in cumulative infections over 6 months are shown on the left; reductions in deaths

are shown on the right.

Figure 3: The percentage reduction in cumulative infections after 6 months of simulation,

relative to no mask use in the population, as mask use varies in the general, susceptible

population for different types of face masks. Mask source control parameters are fixed

according to estimates for the given types, and wearer protection efficiency is assumed to be half

of source control effectiveness. In this analysis, younger susceptible persons are assumed to use

masks at 70% of the rate of persons ≥65 years old. Known infected people ≥65 years old are

masked at a 90% rate, with younger persons at 70%.

Figure 4: Effective reproduction number for given mask use by varying efficacy parameters

shown on the horizontal and vertical axes. This analysis assumes 90% and 70% mask use rates

for infectious and detected persons older and younger than 65 years of age, respectively, and

80% and 60% among susceptible persons for the same age breakdown. Asymptomatic detection

and symptomatic awareness fractions are given in Table 1. The baseline R_0 in the absence of

mask use is assumed to be 2.5 in the left panel and 4.0 in the right panel.

Figure 1

Figure 2

Figure 3

Figure 4